Two Siemens execs tapped for MITA leadership

Clint vanSonnenberg | | Health Imaging | Practice Management
The Medical Imaging Technology Alliance (MITA) has selected Siemens US CEO Randy Hill and director of marketing and strategic relationships for the Americas Henri Primo to assume leadership roles in developing standards for imaging equipment.

Hill, who is in charge of sales, marketing and service for Siemens US, will serve as chair of the MITA Board. Set to enter his sixth term as chair of the medical imaging informatics section, Primo will continue to oversee workgroups focused on formulating standards related to issues of privacy and security in imaging informatics.

MITA prepares and advocates for standards and guidelines for medical imaging equipment and is a division of the National Electrical Manufacturers Association (NEMA).

Clint vanSonnenberg

Related Content

Newly launched report feature provides patients with a visual aid to their imaging
Center for Devices and Radiological Health hit with federal job cuts
Overview of the regulatory landscape of AI in radiology
Concerns about private equity's growing influence in radiology
'Ad hoc' shifts and radiology 'maestros': How one department addressed its workflow hiccups
Not all lead glasses are created equal

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.